H.C. Wainwright lowered the firm’s price target on Spero Therapeutics (SPRO) to $5 from $7 and keeps a Buy rating on the shares. The company’s SPR720 Phase 2a data disappointed, the analyst tells investors in a research note. The firm completely remoted the candidate from its valuation assessment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRO: